Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer
- PMID: 17920715
- DOI: 10.1016/j.radonc.2007.09.010
Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer
Abstract
Background and purpose: Fractionation strategies delivered over 4 weeks are of clinical and radiobiological interest because treatment is completed before radiotherapy (RT) induced clonogen proliferation commences in earnest approximately 3 to 4 weeks into a course of RT. We wished to test the clinical hypothesis that an increased total dose delivered over 4 weeks with smaller than standard doses per fraction in locally advanced squamous cell carcinoma (SCC) may result in relative protection of late responding tissues and an increased tumor control compared to a conventional daily course in the same overall time.
Materials and methods: Between 1988 and 1995 a randomized controlled trial employing RT alone was undertaken at the Princess Margaret Hospital that included 331 eligible patients with T3 or T4 N0 or any N-positive oropharynx, hypopharynx, or larynx primary SCC. RT was randomly assigned to one of two 4 week schedules, either 51 Gy in 20 equal daily fractions, termed conventional fractionation (CF), or 58 Gy in 40 equal fractions given twice per day as a hyperfractionated (HF) experimental arm.
Results: The 5-year local relapse rate was reduced in the HF (41%) compared to the CF arm (49%). This difference was marginally not significant (p=0.082) when the effect was not adjusted. When the effect of the treatment was adjusted by Cox model for clinical factors that included N-category, ECOG performance status, site of disease, T-category, age, hemoglobin, and gender the HF achieved a significant effect (p=0.02). Survival (40% vs. 30%) was also improved with HF compared to CF arm. This difference was only marginally not significant (p=0.069) but again achieved statistical significance when the model was adjusted for clinical factors (p=0.01). Similar results were observed for disease free survival. Although reversible acute toxicity was increased with HF, the overall 5-year rate of grade 3 and 4 late toxicity for the CF was 10.5% compared to 7.7% in the higher dose HF arm.
Conclusions: HF delivered in 4 weeks permits enhanced RT doses achieving improved tumor control, without increased late toxicity, compared to daily fractionated radiotherapy in the same overall time.
Similar articles
-
[Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers].Bull Acad Natl Med. 1998;182(6):1247-60; discussion 1261. Bull Acad Natl Med. 1998. PMID: 9812410 Clinical Trial. French.
-
A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.Radiother Oncol. 2005 Apr;75(1):34-43. doi: 10.1016/j.radonc.2004.11.003. Epub 2004 Nov 25. Radiother Oncol. 2005. PMID: 15878099 Clinical Trial.
-
Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):762-71. doi: 10.1016/j.ijrobp.2004.07.682. Int J Radiat Oncol Biol Phys. 2005. PMID: 15708255 Clinical Trial.
-
Evidence-based radiation oncology in head and neck squamous cell carcinoma.Radiother Oncol. 2007 Oct;85(1):156-70. doi: 10.1016/j.radonc.2007.04.002. Epub 2007 May 4. Radiother Oncol. 2007. PMID: 17482300 Review.
-
[Study on clinical application of multiple fractions per day radiation therapy with concomitant boost technique for esophageal cancer].Hokkaido Igaku Zasshi. 1993 Jul;68(4):537-56. Hokkaido Igaku Zasshi. 1993. PMID: 8340051 Review. Japanese.
Cited by
-
Radiotherapy-Activated Hafnium Oxide Nanoparticles Produce Abscopal Effect in a Mouse Colorectal Cancer Model.Int J Nanomedicine. 2020 May 29;15:3843-3850. doi: 10.2147/IJN.S250490. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32581534 Free PMC article.
-
MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1.PLoS One. 2013;8(1):e53765. doi: 10.1371/journal.pone.0053765. Epub 2013 Jan 15. PLoS One. 2013. PMID: 23335975 Free PMC article.
-
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. eCollection 2020. Front Immunol. 2020. PMID: 33117354 Free PMC article. Review.
-
Status quo and directions in deep head and neck hyperthermia.Radiat Oncol. 2016 Feb 11;11:21. doi: 10.1186/s13014-016-0588-8. Radiat Oncol. 2016. PMID: 26868027 Free PMC article. Review.
-
The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors.J Oncol. 2019 Apr 28;2019:4304817. doi: 10.1155/2019/4304817. eCollection 2019. J Oncol. 2019. PMID: 31182960 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous